TP-03 (lotilaner)
Demodex Blepharitis
Phase 3Asset for Sale/Partnership
Key Facts
About LianBio
LianBio's mission was to accelerate the availability of innovative medicines for patients in China and broader Asian markets by in-licensing clinical-stage assets from global partners. The company built an integrated regional development and commercialization platform to navigate complex regulatory and commercial landscapes. Its primary achievement was advancing a portfolio of promising candidates, including mavacamten for oHCM which reached NDA acceptance in China, before the Board's decision to wind down operations and liquidate the pipeline following a strategic review in November 2023.
View full company profileTherapeutic Areas
Other Demodex Blepharitis Drugs
| Drug | Company | Phase |
|---|---|---|
| XDEMVY (TP-03) | Tarsus Pharmaceuticals | Commercial |